1Mo·

Why should I care about what I said yesterday?

70 percent of my portfolio is $NVDA (+2,58 %) —I’ve never really cared about that before. “I’ll hold onto this at least until 2030” was my motto. Because I consider it one of the best stocks in the world.

And what did I do yesterday? I sold 20 percent of the position and added three new stocks to my portfolio: $SAP (-2,44 %)
$UCG (+0,67 %)
$MUFG (+2,85 %)

Why?

Because I think the risk is too high that meme stocks like SpaceX will first suck up all the money and then cause the bubble (which we’ve identified) to burst in a way that drags down fundamentally sound stocks as well.

And because I’m too old for that kind of crap: diversify.

Sure, the concentration is still huge, but it’s a start. If the madness on the stock market continues to drive the herd, I’ll keep selling off NVIDIA, but not everything. I’ll keep 40 percent.

I actually wanted to pick up something in the healthcare sector, but couldn’t find anything attractive.

01.07

MUFG

Acheté x3000 à 17,51 €

52 533,00 €

7 Commentaires

Johnny B.@JBatelli

1Mo

A very good decision. And right away, large sums were reinvested in a few strong companies. That's the way to do it!
In the healthcare sector, maybe Stryker. It's a good compounder. And it's currently relatively undervalued.

•

Soprano@Soprano

1Mo

Just ask me. The highest-quality pharmaceutical stocks are $VRTX and $ABBV; as an NVIDIA bull, perhaps $ISRG; for defensive investors, $SYK and $TMO; and anyone looking to speculate on multibaggers should buy $MEDP

•

Gomerdoc@Gomerdoc

@Soprano The best pharmaceutical stocks in terms of quality?
Definitely not.
Maybe the ones that can generate the highest profits by betting on the future.

I can recommend something else to you:$ATTO, which has been on the NASDAQ for two days.
They’re going to make a big splash soon—take it from someone who knows someone at the very top there extremely well and has known them for a very long time 😊😉

And still, I’d always recommend $AMG, as well as the likes of $SYK and $JNJ in the pharma sector. All those smaller companies mentioned above will simply be swallowed up by Amgen or Johnson & Johnson if something cool comes along.
For many of these somewhat “smaller” biotech companies, “exit into Big Pharma” is already the internally communicated goal of the founders right from the IPO.

And the thread starter did write that he’s “too old for this crap”:
If you’re looking for stability, long-term growth with minimal risk, and global market leadership, you’re best off buying Amgen and Johnson & Johnson.
Maybe a little bit of $ROP and $NOVO B as well. Or a little bit of $ECL.

••

Soprano@Soprano

@Gomerdoc Sorry, but was this post written under the influence of alcohol or other intoxicating substances from the pharmaceutical companies in question?

AbbVie, that “little fly-by-night operation,” has a market cap of 400 billion—roughly twice the size of Amgen. No one could possibly take it over. Not even JNJ could ever pull off a takeover like that.

It’s a bit like Meta trying to take over the “little startup” Apple.

••

Get_Rich_or_Die_Tryin@Get_Rich_or_Die_Tryin

1Mo

$PME, $SOBI, $MEDI. You can thank me later.😉 All are attractively valued and have significant upside. Two-thirds are MedTech heavyweights; Sobi is the world’s leading orphan drug company.🤷🏼‍♂️

•

Null@Frei

1Mo

I'm no expert, but could the financial sector be taking measures to protect itself from a bubble? 🤔

•

Charmin@Charmin

1Mo

@Frei I was referring to the AI bubble; I don't currently see a bubble that directly affects financial stocks. On the contrary: The likelihood of rising interest rates is high—I think that would actually help the banks.

••